Efficacy of Mavacamten on functional capacity in hypertrophic cardiomyopathy: a meta-analysis, meta-regression, and trial sequential analysis of randomized controlled trials
Ibrahim Khalil, Anannya Sheikh, Nabila Nur, Imran Hossain, Mahmuda Akter, Sajjad Ghanim Al-Badri · 2026
Read Efficacy of Mavacamten on functional capacity in hypertrophic cardiomyopathy: a meta-analysis, meta-regression, and trial sequential analysis of randomized controlled trials by Ibrahim Khalil, Anannya Sheikh, Nabila Nur, Imran Hossain, Mahmuda Akter, Sajjad Ghanim Al-Badri (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/PMC13354381.txt.
Description
Ibrahim Khalil leads a 2026 pooled analysis of mavacamten and exercise capacity in hypertrophic cardiomyopathy. The thickened heart muscle disease can block outflow, cause heart failure, and trigger sudden death, while mavacamten targets the muscle motor directly. Six randomised trials to August 1, 2025 compared the drug with placebo in adults.
Across 632 patients, outflow gradients fell sharply: by 38.28 mmHg after exercise and by 44.50 mmHg at rest, as mean differences. A heart strain marker, NT-proBNP, dropped by 617.26 ng/L. Oxygen uptake, ejection fraction, and serious harms were also pooled. Extra regression and sequential checks probed moderators and result firmness.
Catalog record
| CREATOR | Ibrahim Khalil, Anannya Sheikh, Nabila Nur, Imran Hossain, Mahmuda Akter, Sajjad Ghanim Al-Badri |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 57127 |
| LICENSE | https://creativecommons.org/licenses/by/4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |